LENZ Therapeutics and JIXING Announce Exclusive License Agreement for Greater China; RTW invests in LENZ Therapeutics | National – Tips & Results

SAN DIEGO & SHANGHAI & NEW YORK–(BUSINESS WIRE)–Aug. April 2022–

LENZ Therapeutics (LENZ), a biopharmaceutical company with a lead late-stage clinical program representing a potential best-in-class therapy for presbyopia, announced today that it has entered into an exclusive licensing agreement with Ji Xing Pharmaceuticals (JIXING) for Has completed development and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment of presbyopia in Greater China. JIXING is a biotechnology company headquartered in Shanghai and backed by RTW Investments, LP (RTW), a leading healthcare investment firm focused on advancing innovative medicines for ophthalmic and cardiovascular patients in China. In addition, RTW will invest US$10 million in LENZ Therapeutics.

Under the terms of the license agreement, LENZ will receive upfront payments of US$15 million and potentially additional payments of up to US$95 million based on various mandatory development, regulatory and commercial milestones and royalties based on future net sales.

“We are very excited to be collaborating with JIXING and bringing our products together to one of the largest presbyopia markets in the world,” said Eef Schimmelpennink, CEO of LENZ Therapeutics. “Furthermore, RTW’s investment underscores LENZ’s promise to become a global leader based on its potentially best-in-class aceclidine presbyopia eye drops.”

“Age-related eye diseases are a growing challenge in China, with an estimated 440 million patients suffering from presbyopia,” said Joseph Romanelli, CEO of JIXING. “We have built a portfolio in the areas of presbyopia and dry eye and will continue to expand into more critical eye disease areas. Our goal is to use disruptive science to improve the standard of care for patients in China. Today’s cooperation with LENZ is another milestone in fulfilling this obligation.”

“We are excited to partner with pioneering companies like LENZ to advance medical innovations in eye care that benefit more patients around the world,” said Roderick Wong, MD, Chairman of JIXING and Managing Partner of RTW. “Through this strategic alliance, we look forward to supporting LENZ in expanding its global reach.”

About LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine)

Aceclidine is a small molecule acetylcholine receptor agonist that causes pupillary contraction or miosis and creates a pinhole effect that improves near vision. Studies have shown that the mechanism of action of aceclidine (MOA) is ideally positioned to produce a pinhole pupil effect while avoiding myopia shift. It is crucial to minimize myopia shift as it can significantly impair distance vision for the majority of presbyopes.

Aceclidine’s unique MOA, in which miosis is decoupled from myopia shift, is expected to allow it to target the broadest patient population.

In clinical studies, LENZ has shown that improvement in near vision correlates with aceclidine’s ability to maintain a pupil sweet spot of 1.5mm to 2mm for at least seven hours. There was no loss and a slight trend towards a net gain in the best corrected distance view. In addition, aceclidine was well tolerated, with no serious side effects and with mild discomfort upon instillation being the most common side effect.

LENZ’s INSIGHT clinical trial will serve as the confirmatory lead-in for its Phase 3 trial, which is planned for the second half of 2022.

About LENZ

LENZ is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Its lead programs, LNZ100 and LNZ101, are aceclidine-based eye drops designed to restore near vision loss associated with presbyopia. Presbyopia is estimated to affect nearly two billion people worldwide and more than 120 million people in the United States. Headquartered in San Diego, California, LENZ is backed by world-class venture capital investors for the development and commercialization of the LNZ100 and LNZ101. Further information can be found at: LENZ-Tx.com.

About JIXING

JIXING is a Shanghai-headquartered biopharmaceutical company committed to bringing innovative science and medicines to underserved patients suffering from serious and life-threatening diseases in China. Founded in 2019 with support from RTW Investments, LP, JIXING partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics to address unmet medical needs in cardiovascular and eye diseases. With a strong and evolving asset pipeline, an experienced management team and a patient-centric focus, JIXING strives to create a meaningful and lasting impact on patients in Greater China. For more information on JIXING, please visit www.jixingbio.com.

About RTW

RTW Investments, LP (RTW) is a New York-based global lifecycle investment firm focused on identifying transformative and disruptive innovations in the biopharmaceutical and medical device sectors. As a leading partner of industry and science, RTW combines profound scientific expertise with a solution-oriented investment approach to advance new medical therapies by building and supporting the companies and/or scientists who develop them. For more information about RTW, visit www.RTWfunds.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005149/en/

CONTACT: Shawn Olsson

LENZ therapeutics

IR@LENZ-Tx.com Josh Baldwin

Manager, Communications

RTW investments

(332) 910-7844

jjgb@rtwfunds.com Ji Xing Pharmaceuticals

media@jixingbio.com

KEY WORD: CALIFORNIA NEW YORK NORTH AMERICA UNITED STATES ASIA PACIFIC CHINA CANADA

INDUSTRY KEY WORD: BIOTECHNOLOGY PROFESSIONAL SERVICES HEALTH GENERAL HEALTH PHARMACEUTICAL OPTICAL RESEARCH INFECTIOUS DISEASES SCIENCE CLINICAL TRIAL FUNDING

SOURCE: LENZ Therapeutics

Copyright Business Wire 2022.

PUB: 04/13/2022 07:00 / DISC: 04/13/2022 07:02

http://www.businesswire.com/news/home/20220413005149/en

Leave a Comment